NYSE · GKOS
Glaukos Corporation
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for GKOS has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Dec 2026 | $0.13 | $0.18 | $0.03 | 5 |
| Mar 2027 | $0.00 | $0.05 | $-0.04 | 3 |
| Jun 2027 | $0.11 | $0.21 | $0.05 | 3 |
| Sep 2027 | $0.09 | $0.11 | $0.05 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
BNK Invest · The Motley Fool · RTTNews · Zacks- BNK Invest · Oct 30, 6:20 AM EDTGKOS Crosses Above Average Analyst TargetIn recent trading, shares of Glaukos Corp (Symbol: GKOS) have crossed above the average analyst 12-month target price of $195.53, changing hands for $242.48/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valua
- The Motley Fool · Oct 29, 3:50 PM EDTGlaukos Sets $1 Billion 2027 Sales Goal: Rapid Earnings ReactionGlaukos raised its 2026 sales forecast to $775 million to $785 million and set a preliminary 2027 target of $1 billion, after third-quarter sales jumped 58% to $211.0 million.
- RTTNews · Oct 29, 3:40 PM EDTHealthcare Stocks Rise: GKOS Surges 33%, TDOC Gains 30%, BHC Advances 26%, MESO Jumps Over 16%(RTTNews) – Shares of several healthcare companies moved higher following quarterly financial results and business updates. Glaukos raised its 2026 sales guidance and issued a preliminary outlook for 2027, Teladoc Health reported improved adjusted EBITDA, Bausch Health posted hig
- Zacks · Oct 29, 11:04 AM EDTWest Pharma Q3 Earnings Rise on HVP Strength, 2026 Outlook RaisedWST reports strong Q3 earnings and revenue growth, fueled by high-value products and margin expansion, and raises its 2026 sales and earnings outlook.
- RTTNews · Oct 29, 5:33 AM EDTGlaukos Swings To Profit In Q3, Lifts Full-Year 2026 Guidance; Shares Surge Pre-Market(RTTNews) – Glaukos Corp. (GKOS), an ophthalmic pharmaceutical and medical technology company, announced third-quarter 2026 financial results, reporting 58% revenue growth, a return to profitability, and increased full-year 2026 revenue guidance.
- The Motley Fool · Oct 28, 11:59 PM EDTGlaukos (GKOS) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Fintel · Oct 28, 9:41 PM EDTGlaukos Corporation Reports Record Q3 2026 Net Sales of $211.0 Million and Raises Full-Year GuidanceGlaukos Corporation announced its financial results for the third quarter ended September 30, 2026, reporting record net sales of $211.0 million, representing a 58% increase year-over-year on a reported and constant currency basis. The growth was driven by U.S. Glaucoma net sales
- MarketBeat · Oct 28, 7:04 PM EDTGlaukos Q3 Earnings Call HighlightsGlaukos (NYSE:GKOS) reported record third-quarter consolidated net sales of $211 million, up 58% from the year-earlier period, led by growth in its Epioxa corneal health therapy and iDose TR glaucoma treatment. The company raised its full-year 2026 revenue outlook and introduced
- Zacks · Oct 28, 6:30 PM EDTGlaukos (GKOS) Q3 Earnings and Revenues Surpass EstimatesGlaukos (GKOS) delivered earnings and revenue surprises of +491.67% and +24.99%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Oct 28, 6:00 PM EDTCompared to Estimates, Glaukos (GKOS) Q3 Earnings: A Look at Key MetricsThe headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- Zacks · Oct 28, 11:16 AM EDTSYK Q3 Earnings: Can Recovery Momentum Offset Operational Headwinds?SYK's Q3 earnings may reflect strong hospital equipment demand and cybersecurity recovery, but supply constraints, vascular disruptions and margin pressures remain.
- Zacks · Oct 28, 11:16 AM EDTProDex Q1 Earnings Preview: Can Strong Sales Momentum Sustain Growth?PDEX heads into fiscal Q1 earnings with strong medical-device sales and margin momentum, but customer concentration, a shrinking backlog and acquisition risks loom.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Glaukos Corporation from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.